IRIS
BERARDI, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.502
EU - Europa 13.816
AS - Asia 12.003
SA - Sud America 2.872
AF - Africa 714
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 19
Totale 57.946
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.004
RU - Federazione Russa 4.099
SG - Singapore 3.961
VN - Vietnam 2.459
BR - Brasile 2.257
IT - Italia 2.218
CN - Cina 1.902
UA - Ucraina 1.357
HK - Hong Kong 1.269
DE - Germania 1.179
IE - Irlanda 1.078
SE - Svezia 845
FR - Francia 720
FI - Finlandia 661
TR - Turchia 583
GB - Regno Unito 515
DK - Danimarca 457
IN - India 387
BD - Bangladesh 326
CI - Costa d'Avorio 305
KR - Corea 272
CA - Canada 261
AR - Argentina 233
NL - Olanda 155
MX - Messico 144
PL - Polonia 134
JP - Giappone 130
ZA - Sudafrica 123
MA - Marocco 115
IQ - Iraq 109
ID - Indonesia 108
EC - Ecuador 100
CO - Colombia 87
PK - Pakistan 78
BE - Belgio 69
ES - Italia 69
AT - Austria 63
UZ - Uzbekistan 54
PH - Filippine 49
CL - Cile 47
VE - Venezuela 47
PY - Paraguay 39
KE - Kenya 32
RO - Romania 31
SA - Arabia Saudita 31
TN - Tunisia 31
AZ - Azerbaigian 30
MY - Malesia 30
PE - Perù 30
EG - Egitto 28
JO - Giordania 26
DZ - Algeria 25
LT - Lituania 24
AE - Emirati Arabi Uniti 23
KZ - Kazakistan 23
CR - Costa Rica 21
NP - Nepal 20
UY - Uruguay 19
CZ - Repubblica Ceca 18
TH - Thailandia 17
JM - Giamaica 15
SK - Slovacchia (Repubblica Slovacca) 14
TW - Taiwan 14
EU - Europa 13
IL - Israele 13
AL - Albania 12
AU - Australia 12
KG - Kirghizistan 12
CH - Svizzera 11
HN - Honduras 11
PS - Palestinian Territory 10
PT - Portogallo 10
RS - Serbia 10
BG - Bulgaria 9
BH - Bahrain 9
BO - Bolivia 9
BY - Bielorussia 9
DO - Repubblica Dominicana 9
ET - Etiopia 9
LB - Libano 9
PR - Porto Rico 9
GR - Grecia 8
SN - Senegal 8
NG - Nigeria 7
NZ - Nuova Zelanda 7
BA - Bosnia-Erzegovina 6
HR - Croazia 6
KW - Kuwait 6
LY - Libia 6
OM - Oman 6
SI - Slovenia 6
CY - Cipro 5
GE - Georgia 5
NI - Nicaragua 5
PA - Panama 5
SV - El Salvador 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
AO - Angola 4
BW - Botswana 4
Totale 57.864
Salva come PNG Salva come JPEG
Città #
Ashburn 4.777
Dallas 2.568
Singapore 2.559
Chandler 2.048
Jacksonville 1.508
Fairfield 1.487
San Jose 1.371
Hong Kong 1.229
Des Moines 1.180
Dublin 1.069
Boardman 994
Ho Chi Minh City 784
Wilmington 732
New York 705
Council Bluffs 704
Woodbridge 660
Seattle 648
Houston 613
Hanoi 568
The Dalles 523
Ann Arbor 495
Cambridge 480
Los Angeles 467
Beijing 465
Lauterbourg 416
Lawrence 388
Princeton 388
Munich 367
San Mateo 364
Moscow 343
Abidjan 305
Helsinki 288
Hefei 231
Milan 224
Centro 217
São Paulo 210
San Diego 184
Buffalo 182
Santa Clara 162
Chicago 156
London 142
Turku 137
Da Nang 132
Rome 127
Ancona 122
Orem 122
Turin 122
Warsaw 119
Haiphong 117
Pune 106
Washington 105
Tokyo 101
Chennai 81
Montreal 80
Rio de Janeiro 79
Johannesburg 71
Guangzhou 70
Frankfurt am Main 69
Brussels 65
Denver 65
Shanghai 63
Brooklyn 62
Nuremberg 60
Atlanta 59
Vancouver 56
Columbus 53
Poplar 53
Miano 52
Belo Horizonte 50
Hải Dương 49
Phoenix 47
Stockholm 47
Tashkent 46
Mexico City 45
Amsterdam 42
Boston 42
Baghdad 41
Manchester 41
Marche 41
Falls Church 40
Biên Hòa 39
Norwalk 38
Brasília 37
Elk Grove Village 37
Salt Lake City 36
San Francisco 35
Curitiba 34
Wuhan 34
Dhaka 33
Mumbai 33
Quito 33
Porto Alegre 32
Toronto 32
Urbisaglia 31
Naples 29
Thái Nguyên 29
Ankara 28
Nairobi 28
Baku 27
Guayaquil 27
Totale 36.732
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 2.287
Contrasting Digital Fake News in Health: an Interdisciplinary Approach 829
Contrasting Fake News in Oncology: The First Declaration of Good Communication 813
The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer 284
A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy 276
Metabolic phenotype of bladder cancer 262
Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature 240
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 226
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 219
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 213
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach 206
Impact of polypharmacy for chronic ailments in colon cancer patients: A review focused on drug repurposing. 206
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 201
Are liver nested stromal epithelial tumors always low aggressive? 201
Clinical impact of different exosomes’ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy 201
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 197
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 197
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 195
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study 195
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature 194
Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: a systematic review and meta-analysis 193
A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay 191
Optimal management of resected gastric cancer 188
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 187
Role of DCE-MR in predicting breast cancer subtypes. 187
The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases 187
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 187
Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia 184
Syndrome of inappropriate antidiuretic hormone secretion (Siadh): Optimal management 183
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 182
Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy 181
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 181
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors 180
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 176
5-Fluorouracil pharmacogenomics: still rocking after all these years? 175
Developments in the management of advanced soft-tissue sarcoma –€“ Olaratumab in context 173
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients 171
Long‑responders to anti‑HER2 therapies: A case report and review of the literature 171
Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO) 169
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 168
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 168
Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Correlated Hypokalaemia 168
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 168
Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic 167
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 166
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 166
The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis 166
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 166
A cost-benefit analysis of chemotherapy for gastric cancer. 165
Gender Differences and Outcomes in Melanoma Patients 163
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab 163
An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer 163
Role of DCE-MR imaging of the breast in predicting breast cancer subtypes: where are we going? 162
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 162
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 161
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 161
Electrolyte disorders in cancer patients: a systematic review 160
Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data 159
Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer 159
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 157
The impact of lifestyle interventions in high‐risk early breast cancer patients: A modeling approach from a single institution experience 157
Squamous cell carcinoma of the lung: clinical criteria for treatment strategy 156
Adjuvant treatment after surgical resection 156
Medical treatment for cholangiocarcinoma 154
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 153
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study 153
Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study 153
Benefits and limitations of a multidisciplinary approach in cancer patient management 153
Seminoma Retroperitoneal Relapse 23 Years After Surgery 153
Lynphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. 152
Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis 152
Managing hyponatremia in lung cancer: latest evidence and clinical implications 151
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 151
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients 151
Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival 150
Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. 149
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review 149
High CTLA-4 expression correlates with poor prognosis in thymoma patients 149
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 148
Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma 147
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions 147
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 147
Randomized active-controlled phase 2 study of Denosumab efficacy and safety in patients with breast cancer-related bone metastases. 146
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 146
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 146
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 146
Gender differences and outcome of melanoma patients 145
Systemic treatment for lung carcinoids: from bench to bedside 145
Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients 145
A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial 145
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 145
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 144
Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer 144
New target therapies in advanced pancreatic cancer. 143
Hyponatremia in cancer patients: Time for a new approach 143
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer 143
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 142
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 142
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 142
Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex 142
Totale 20.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 257.386
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 257.386
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.052 169 639 78 98 42 224 124 209 303 207 328 631
2022/20236.355 518 648 404 531 338 1.618 2 325 1.357 58 411 145
2023/20243.659 580 83 234 408 574 877 52 132 10 131 51 527
2024/20258.278 851 754 371 158 339 357 692 323 1.948 658 824 1.003
2025/202626.712 1.508 1.944 2.531 2.583 2.424 1.579 4.136 2.244 3.946 1.974 826 1.017
2026/2027534 534 0 0 0 0 0 0 0 0 0 0 0
Totale 59.040